Day Trading Reports
  • Business
  • World News
  • Politics
  • Investing
  • Business
  • World News
  • Politics
  • Investing

Day Trading Reports

Investing

RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

by admin June 4, 2025
June 4, 2025
RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Radiopharm Theranostics (RAD:AU) has announced RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Download the PDF here.

This post appeared first on investingnews.com

previous post
Byron Allen puts broadcast TV stations up for sale
next post
China’s Breakthrough in Uranium Seawater Extraction Boosts Efficiency by 40 Times

Related Posts

Stardust Power Shares Boosted by Sumitomo Lithium Offtake...

February 6, 2025

Quimbaya Gold Announces Strategic Private Placement of up...

May 29, 2025

Silver Crown Royalties Announces Closing of Second Tranche...

March 31, 2025

Falco Announces Extension of Certain Deadlines and Other...

February 1, 2025

Web3 Leaders Gather in Toronto for Canada Crypto...

May 13, 2025

Cleantech Market Update: Q1 2025 in Review

April 14, 2025

Are We in a Recession? Predictions, Signs and...

April 29, 2025

MXR: Extension of Takeover Offer Period

March 7, 2025

Zijin to Take on Precious Metals Streaming as...

May 28, 2025

New RAD202 data confirms positive tumor uptake

March 17, 2025

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Editors’ Picks

    • 1

      Forum Energy Metals and Global Uranium Announce Exploration Update on Drill Targeting, Northwest Athabasca Project, Saskatchewan

      January 31, 2025
    • 2

      Mega M&A: Rio Tinto-Glencore Merger Sparks Chatter

      January 28, 2025
    • 3

      Excellent 90% recoveries at Cork Tree Well & Board Update

      February 17, 2025
    • 4

      Financial Agreement signed releasing $2M grant

      January 23, 2025
    • 5

      Netflix shares soar as company reports surging revenue, tops 300 million subscribers

      January 23, 2025
    • 6

      Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

      January 23, 2025
    • 7

      FDA officially authorizes Zyn nicotine pouches for sale following health review

      January 23, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: daytradingreports.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 daytradingreports.com | All Rights Reserved